Buy Tafecta (Tenofovir Alafenamide) 25 mg online, Buy Vemlidy online
Tafecta is the alternative & generic version of Vemlidy by Gilead Sciences. Tafecta is manufactured by Beacon Pharmaceuticals Bangladesh which is the biggest pharmaceutical company in Bangladesh.
Tafecta (Tenofovir Alafenamide) by Beacon Pharmaceuticals is used to treat chronic hepatitis b virus (HBV) infection in adults with compensated liver disease.
Therapeutic Class
Hepatic viral infections (Hepatitis B)
Pharmacology
Tenofovir alafenamide is a phosphonamidate prodrug of tenofovir (2′-deoxyadenosine monophosphate analog). Tenofovir alafenamide as a lipophilic cell-permeant compound enters primary hepatocytes by passive diffusion and by the hepatic uptake transporters OATP1B1 and OATP1B3.
Tenofovir alafenamide is then converted to tenofovir through hydrolysis primarily by carboxylesterase 1 (CES1) in primary hepatocytes. Intracellular tenofovir is subsequently phosphorylated by cellular kinases to the pharmacologically active metabolite tenofovir diphosphate.
Tenofovir diphosphate inhibits HBV replication through incorporation into viral DNA by the HBV reverse transcriptase, which results in DNA chain-termination.
Tenofovir diphosphate is a weak inhibitor of mammalian DNA polymerases that include mitochondrial DNA polymerase γ and there is no evidence of toxicity to mitochondria in cell culture.
Dosage & Administration
Testing Prior To Initiation Of Tenofovir Alafenamide: Prior to initiation of Tenofovir Alafenamide, patients should be tested for HIV-1 infection. Tenofovir Alafenamide alone should not be used in patients with HIV infection
It is recommended that serum creatinine, serum phosphorous, estimated creatinine clearance, urine glucose, and urine protein be assessed before initiating Tenofovir Alafenamide and during therapy in all patients as clinically appropriate
Recommended Dosage In Adults: The recommended dosage of Tenofovir Alafenamide is 25 mg (one tablet) taken orally once daily with food
Interaction
Tenofovir / vemlidy is a substrate of P-glycoprotein (P-gp) and BCRP. Drugs that strongly affect P-gp and BCRP activity may lead to changes in Tenofovir absorption. Consult the full prescribing information prior to and during treatment for potential drug drug interactions.
Contraindications
None
Side Effects
The following adverse reactions are discussed in other sections of the labeling:
-
Lactic Acidosis/Severe Hepatomegaly with Steatosis
-
Severe Acute Exacerbation of Hepatitis B
-
New Onset or Worsening of Renal Impairment